相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical relevance of KRAS mutations in codon 13: Where are we?
Tze-Kiong Er et al.
CANCER LETTERS (2014)
Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer
Jianfei Wang et al.
CANCER BIOMARKERS (2013)
Colon and Rectal Cancer Survival by Tumor Location and Microsatellite Instability: The Colon Cancer Family Registry
Amanda I. Phipps et al.
DISEASES OF THE COLON & RECTUM (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
Chih-Chieh Chen et al.
PLOS ONE (2013)
Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine
Yinchen Shen et al.
PLOS ONE (2013)
Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population
Li-Ling Hsieh et al.
CLINICA CHIMICA ACTA (2012)
Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
Yu Imamura et al.
CLINICAL CANCER RESEARCH (2012)
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
Shuji Ogino et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2012)
Detection of KRAS Mutations and Their Associations with Clinicopathological Features and Survival in Chinese Colorectal Cancer Patients
Z. Li et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer
Chen Mao et al.
PLOS ONE (2012)
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
Yu-Fen Zhu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
T. Yokota et al.
BRITISH JOURNAL OF CANCER (2011)
Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients
Jing Gao et al.
CHINESE JOURNAL OF CANCER RESEARCH (2011)
Gene Expression Differences between Colon and Rectum Tumors
Rebeca Sanz-Pamplona et al.
CLINICAL CANCER RESEARCH (2011)
Frequency of KRAS, BRAF, and NRAS Mutations in Colorectal Cancer
Cecily P. Vaughn et al.
GENES CHROMOSOMES & CANCER (2011)
Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population
Jyh-Ming Liou et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients
Hong Shen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
A. Farina-Sarasqueta et al.
ANNALS OF ONCOLOGY (2010)
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
Inti Zlobec et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
Youji He et al.
CLINICAL CANCER RESEARCH (2009)
KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
Shuji Ogino et al.
CLINICAL CANCER RESEARCH (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
Shuji Ogino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Andrea Sartore-Bianchi et al.
PLOS ONE (2009)
Asia Pacific consensus recommendations for colorectal cancer screening
J. J. Y. Sung et al.
GUT (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer
Shunsuke Kato et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Gender differences in colorectal cancer: implications for age at initiation of screening
H. Brenner et al.
BRITISH JOURNAL OF CANCER (2007)
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype
V Bazan et al.
ANNALS OF ONCOLOGY (2002)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
分享论文
